ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma
ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
Janux's CEO David Campbell reviews this week's data from JANX007, the company's PSMA x CD3 masked bispecific for prostate cancer
The Co-Founder and CTO of Seoul based Organoid Sciences walks us through how the company is using organoids for regenerative medicine, CRO services, and precision medicine
The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring
Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines
BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans
Led by a longtime leader of Korea's biotech sector, GI Innovation has science-forward programs such as fusion proteins that aim to redefine IL-2 and an IgE trap that could go up against Xolair
Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies
With an experienced researcher at the helm, Seoul-based Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies
London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting
London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections
Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well
Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea
London Healthcare Week: A discussion on treating neurodegenerative diseases with the CEO of AC Immune
London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space
The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi
Visiting the largest cell therapy company in Korea, GC Cell, and learning about its approved immunotherapy for hepatocellular carcinoma, its CAR-NK programs in development, and more
London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program
.png){kind=logo}
